Share Twitter LinkedIn Facebook Email Deepa Jeyakumar, MD, from UC Irvine Health For Multiple Myeloma Research joins us at MOASCs Spotlight On® Hematology in Huntington Beach to discuss the toxicities with IDH1 & IDH2 inhibitors and a new side-effect the IDH differentiation syndrome.
FDA grants accelerated approval to ponatinib (ICLUSIG®) with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia Acute Lymphoblastic Leukemia 3 Mins Read
FDA Approves Inotuzumab Ozogamicin (BESPONSA) for Acute Lymphoblastic Leukemia in Pediatric Patients [Exclusive Video] Acute Lymphoblastic Leukemia 3 Mins Read
Spotlight on CAR T-cell Therapy in 2024: Advances & Clinical Insights Acute Lymphoblastic Leukemia 3 Mins Read